Seeking Alpha
15 Jun 2026, 17:59 UTC · 14w ago
Verdict
Headline takes no side. We score BCRX +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 88% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
BioCryst targets $1.8 billion in revenues and $1 billion in cash by 2033.
So whatLong-term revenue and liquidity targets provide a concrete valuation framework for investors.
More positive than 93% of claims this week
Orladeyo revenue grew 11% year-over-year in the first quarter.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 78% of claims this week
The company is developing navenibart as a best-in-class efficacy treatment with less frequent dosing to challenge market incumbents.
More positive than 65% of claims this week
BioCryst faces risks from intensifying competition and patent expiries occurring after 2030.
So whatFuture patent cliffs create a long-term ceiling on valuation and risk of revenue erosion.
More negative than 70% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
The company was upgraded to a 'Buy' rating due to strong execution in HAE, revenue growth, and a compelling pipeline.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
−1.3%
Price is moving against the score
$8.59 vs $8.70 close before publication (Jun 12) · not market-adjusted
BCRX chart →
